Cargando…

P924: TREATMENT EFFICACY OF PROGRESSION FREE SURVIVAL FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA IN GERIATRIC PATIENTS: A NETWORK META-ANALYSIS

Detalles Bibliográficos
Autores principales:	Lee, C.-H., Ho, C.-L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430587/ http://dx.doi.org/10.1097/01.HS9.0000846564.75755.cb

Ejemplares similares

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2011)

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
por: Yan, Xiaoyu, et al.
Publicado: (2020)

P924: TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY
por: Goyal, Ravi K, et al.
Publicado: (2023)

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
por: Hulin, C., et al.
Publicado: (2022)

P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA
por: Wang, Yi, et al.
Publicado: (2023)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

P20: POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Iula, R, et al.
Publicado: (2022)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Li, C., et al.
Publicado: (2022)

P970: SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
por: Wang, Y., et al.
Publicado: (2022)

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
por: Dhakal, B., et al.
Publicado: (2022)

Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
por: Gao, Xiaohui, et al.
Publicado: (2023)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
por: Asherie, N., et al.
Publicado: (2022)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
por: Furlan, A., et al.
Publicado: (2023)

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
por: Macro, M., et al.
Publicado: (2022)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

P894: A PHASE II TRIAL TO EVALUATE THE EFFICACY OF DARATUMUMAB WITH DCEP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER BORTEZOMIB BASED TREATMENT
por: Byun, J. M., et al.
Publicado: (2022)

P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE
por: Vekemans, M-C, et al.
Publicado: (2022)

How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
por: Attucci, I., et al.
Publicado: (2023)

P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Searle, Emma, et al.
Publicado: (2023)

P953: PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Tang, W., et al.
Publicado: (2022)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma
por: Waldschmidt, Johannes M., et al.
Publicado: (2022)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
por: Suvannasankha, A., et al.
Publicado: (2022)

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
por: White, Darrell, et al.
Publicado: (2023)

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
por: Einsele, H., et al.
Publicado: (2023)

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
por: Bobin, A., et al.
Publicado: (2022)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ielo, C., et al.
Publicado: (2023)

P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY
por: Einsele, H., et al.
Publicado: (2022)

P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY.
por: Fazio, F, et al.
Publicado: (2022)

P902: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY
por: Fazio, F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kvrclon27gv4bnh6arluchp7fc